Document EKxwzEJGYjjp38yR10a6ZQn0

To: David Hunt (E-mail)<dghunt@dow.com> From: Lorraine Twerdok <Twerdokl@api.org> Cc: Patrick Beatty (E-mail) <PWBE@chevrontexaco.com>; Stuart Cagen (E-mail) <szcagen@shellus.com>; Tom Armstrong (E-mail) <twarmst@erenj.com>; Andrew Jaques (E-mail) <andrewjaques@americanchemistry.com> Bcc: Received Date: 2002-05-1 0 19:43: 17 GMT Subject: (API) Benzene study Hi DavidNice to meet you at the VCCEP meeting on Wednesday. I would like to followup and facilitate setting up a meeting, at your convenience, to discuss exposure issues relating to the Shanghai Health Study. I have a call into Tom Armstrong, the PI handling exposure for the studies, to suggest dates he could be available. Could you please check availability with your folks for the following first cut at dates? week of May 20th week of June 3rd week of june 10th Thanks, and I look forward to further discussions on this issue. Regards, Lorraine ****************************** Lorraine E. Twerdok, Ph.D., DABT Manager, Health Sciences American Petroleum Institute 1220 L Street, NW. Washington, DC 20005 tel: 202-682-8344 fax: 202-682-8270 email: twerdokl@api.org <mailto:twerdokl@api.org> SH ELL-MCCLU RG-055360 To: 'Lorraine Twerdok' <Twerdokl@api.org> From: Hunt, David (DG) <DGHUNT@dow.com> Cc: Patrick Beatty (E-mail) <PWBE@chevrontexaco.com>; Stuart Cagen (E-mail) <szcagen@shellus.com>; Tom Armstrong (E-mail) <twarmst@erenj.com>; Andrew Jaques (E-mail) <andrewjaques@americanchemistry.com>; Bloemen, Louis (LJ) <LJBLOEMEN@dow.com>; Budinsky, Robert (RA) <RABudinsky@dow.com>; Collins, Jim (JJ) <JJCollins@dow.com>; Kociba, Richard (RJ) <rkociba@dow.com>; Pottenger, Lynn (LH) <Ipottenger@dow.com>; Baase, Cathy (CM) <cbaase@dow.com>; Bond, Gregory (GG) <GGBOND@dow.com> Bcc: Received Date: 2002-05-1515:23:32 GMT Subject: RE: (API) Benzene study Lorraine, it was nice to meet you again and to receive an update on the API Benzene study / Shanghai Health Study. I have checked, and we are interested in discussing the API Benzene study / Shanghai Health Study. As I had indicated we have significant concerns with this study, not only for how exposure will be handled, but also concerning other aspects. We have identified Tuesday, June 04,2002 (8:00 AM-1 0:00 AM EDT) as a time at which we can have our technical experts available for a presentation and discussion on this study. If you think that additional time is required, I can check on our further availability. We have also made arrangements for this to be a teleconference at our Midland headquarters so that both our US and European based colleagues can participate. We believe that in order to address the issues properly, this presentation should be more than just an overview of the project. I have distributed copies of the presentation you made at our BTX VCCEP meeting last week. We are interested in a presentation of the scientific aspects of the studies (our understanding is that three are planned), the status of the project, the difficulties identified and met, a description of the project organization (committees), contacts, agreements and expectations for buy in from governmental agencies, and the options for participation. In addition we would want to gain an understanding of how the scientific understanding will be improved. Also are there opportunities for modifying aspects of the project to address specific concerns? Cost is also a concern, especially since the cost and scope of the project appears to have significantly increased from the initial inception. We have received information in the past concerning this project, both in the US and in Europe, and do not feel that these issues have been adequately addressed or explained. The following people representing expertise in toxicology and epidemiology are expected to attend for Dow: Louis Bloemen Robert Budinsky Jim Collins Richard Kociba Lynn Pottenger Please let me know if this proposal for a meeting on June 4, 2002, is agreeable, and if we need to discuss additional details for this meeting. SHELL-MCCLURG-055361 Best Regards, David David Hunt The Dow Chemical Company Global EH&S Product Leader Hydrocarbons and Energy (HC&E) 989-636-0190 FAX: 989-636-9899 dghunt@dow.com * Trademark of The Dow Chemical Company -----Original Message----From: Lorraine Twerdok [mailto:Twerdokl@api.org] Sent: Friday, May 10, 2002 3:45 PM To: David Hunt (E-mail) Cc: Patrick Beatty (E-mail); Stuart Cagen (E-mail); Tom Armstrong (E-mail); Andrew Jaques (E-mail) Subject: (API) Benzene study Hi DavidNice to meet you at the VCCEP meeting on Wednesday. I would like to followup and facilitate setting up a meeting, at your convenience, to discuss exposure issues relating to the Shanghai Health Study. I have a call into Tom Armstrong, the PI handling exposure for the studies, to suggest dates he could be available. Could you please check availability with your folks for the following first cut at dates? week of May 20th week of June 3rd week of june 10th Thanks, and I look forward to further discussions on this issue. Regards, Lorraine ****************************** Lorraine E. Twerdok, Ph.D., DABT Manager, Health Sciences American Petroleum Institute 1220 L Street, NW. Washington, DC 20005 tel: 202-682-8344 fax: 202-682-8270 email: twerdokl@api.org <mailto:twerdokl@api.org> SH ELL-MCCLU RG-055362 SH ELL-MCCLU RG-055363